ClinicalTrials.gg
CompletedNCT00448578STARUpdated Dec 9, 2010

Efficacy and Safety of Seroquel and Lithium as Monotherapy in Acute Mania Treatment in Bipolar Disorder Patients

A Phase 3 interventional study of Quetiapine Fumarate and Lithium in Mania and Bipolar Disorder, sponsored by AstraZeneca. Completed at 6 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-12-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing quetiapine in Mania — none open to participants now, none under way, none of them phase 3. quetiapine · Mania.

Enrollment
2nd of 10
150 · median 73
Started
2005
with 2 others
Phase 3
3 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
4 of 10
AstraZeneca

Among the 10 studies testing quetiapine in Mania, this one is the 2nd largest by enrollment, is one of 3 that started in 2005, is one of 3 in phase 3, and was the 4th registered.

Mania

167 studies on the registry are indexed under Mania; 14 are open to participants now.

Browse Mania studies →

Open to participants now

None of the 10 studies testing quetiapine in Mania is open now. The open studies under Mania, anywhere →

About quetiapine

quetiapine: first FDA approval 1997 (SEROQUEL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Mania studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing quetiapine in Mania as a file.
02

Study summary

This is a randomised, double blind, double dummy, multicentre, parallel-group study to compare the efficacy and safety of quetiapine and lithium used as monotherapy in the treatment of mania in patients hospitalised for an acute manic episode. After given of informed consent and undergoing screening procedures, the patients will be randomised into quetiapine or lithium group on Day 1. The efficacy of study treatment on symptoms of mania will be assessed at Day 28. Patients will not permitted to use any psychoactive or antipsychotic medications throughout the study period other than those expressly permitted by the protocol. The patients are required to be hospitalised for the treatment and assessment defined in the protocol. He/She could be discharged from the hospital after Week 2 (i.e. On Day 15) if the investigator believes that it will be clinical appropriate to discharge the patient, that the patient is not suicidal or homicidal, and that the patient could reasonably be expected to continue in the study on an outpatient basis. The patients discharged after Day 15 will be given sufficient study medication for the period from discharge to the next visit. At each centre, the same individual will administer a specific psychiatric assessment for a patient at all study visits in order to reduce variability in rating scale scoring. Before the initiation of the study, a consistency assessment will be done among the investigators who conduct the scale assessment in each centre.

03

Conditions studied

  • Mania
  • Bipolar Disorder

Keywords

  • Acute Mania
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written for study participation, signed by the patient's legal guardian.
  • Both at screening and at randomization (Day 1), had a YMRS total score of at least 20.

Exclusion criteria

Exclusion Criteria:

  • Known intolerance or lack of response to quetiapine or lithium, as judged by the investigator.
  • Known or suspected to quetiapine or lithium.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
150 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Effectiveness of quetiapine fumarate used as monotherapy in treatment of symptoms of acute mania in patients with bipolar disorder by evaluation of the change from baseline in YMRS total score at Day 28 using the last observation carried forward method

Secondary outcomes

  1. The effectiveness of quetiapine used as monotherapy to treat symptoms in patients with acute mania by evaluation of YMRS response rate at Day 28 (LOCF).

07

Study locations

6 sites
  • Research Sites
    Beijing, China
  • Research Site
    Guang Zhou, China
  • Research Site
    Kunming, China
  • Research Site
    Nanjing, China
  • Research Site
    Shanghai, China
  • Research Site
    Wu han, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2007
First posted
Mar 19, 2007
Start
Aug 2005
CompletionActual
Jun 2006
Last update
Dec 9, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00448578
Lead sponsor
AstraZeneca
First posted
Mar 19, 2007
Start date
Aug 2005
Completion
Jun 2006
Last update
Dec 9, 2010

Study contacts

Clara Gu
study chair · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Quetiapine · Lithium

Start the discussion